For research use only. Not for therapeutic Use.
ARN2966 is a potent post-transcriptional modulator of APP expression; reduces expression of APP with resultant lower production of Aβ.
IC50 value:
Target: Aβ
This potent post-transcriptional modulation of APP expression differs from other mechanisms such as inhibition of secretases. Secretase inhibitors have been pursued as disease modifying strategies by a number of pharmaceutical firms but they have encountered numerous setbacks during clinical development. ARN2966 is non toxic, orally absorbable, blood-brain-barrier penetrable, and effective in vitro and in vivo.
| Catalog Number | I000154 |
| CAS Number | 102212-26-0 |
| Synonyms | 2-(pyridin-2-ylmethylamino)phenol |
| Molecular Formula | C12H12N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C12H12N2O/c15-12-7-2-1-6-11(12)14-9-10-5-3-4-8-13-10/h1-8,14-15H,9H2 |
| InChIKey | GXJRVWZNMZGWAQ-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)NCC2=CC=CC=N2)O |
| Reference | [1]. yodeji Asuni, et al. An APP translation modulator ARN2966 reduces BETA-AMYLOID deposition and prevents memory deficits in ALZHEIMER’S DISEASE transgenic mice. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. 2012. |
